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ChemoprophylaxisAbstract The ﬁrst cases of meningococcal meningitis were described in Geneva in 1805 and in New
England in 1806, the causative agent ﬁnally being identiﬁed byAntonWeichselbaum in 1887. The ﬁrst
meningococcal epidemics occurred in sub-Saharan Africa in the early 1900s and periodic outbreaks
continue to occur worldwide today. Neisseria meningitidis colonizes the naso-oropharyngeal mucosa
in approximately 10–20% of healthy individuals. When it invades the bloodstream, meningococcus
has the potential to cause devastating disease. It can affect people of any age, but primarily infects chil-
dren and adolescents. Meningococcemia classically follows an upper respiratory illness consisting of
myalgias, fever, headache, and nausea. It can present as an indolent infection with rapid recovery or
progress within a few hours into a fulminant illness affecting multiple organ systems. As such, menin-
gococcemia is one of the important causes of sepsis. Prior to antibiotic therapy, the disease carried a
70% mortality rate. Despite advances in early diagnosis and treatment, 10–15% of affected patients
die from the disease and another 10–20% are left with severe morbidities (neurologic disability, hear-
ing loss, loss of a limb). Meningococcal disease remains a signiﬁcant global health threat.
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ChemoprophylaxisResume´ Les premiers cas de me´ningite a` me´ningocoques ont e´te´ de´crits a` Gene`ve en 1805 et en Nou-
velle Angleterre en 1806, l’agent causal de la maladie e´tant ﬁnalement identiﬁe´ par Anton Weichsel-
baum en 1887. Les premie`res e´pide´mies de me´ningococcie se sont pre´sente´es en Afrique
subsaharienne au de´but du 20e` sie`cle et des e´pide´mies re´gulie`res se produisent toujours de nos jours
dans le monde. Neisseria meningitidis colonise la muqueuse rhino-oropharynge´e chez 10 a` 20% environ
des personnes en bonne sante´. Lorsqu’elle envahit le syste`me sanguin, Neisseria meningitidis peut prov-
oquer une maladie de´vastatrice. Elle peut affecter des personnes de tout aˆge, mais infecte principale-
ment les enfants et les adolescents. La me´ningococce´mie suit ge´ne´ralement une maladie des voies
respiratoires supe´rieures consistant en myalgie, ﬁe`vre, maux de teˆte et nause´es. Elle peut se pre´senter
sous forme d’infection a` la malignite´ re´duite avec gue´rison rapide ou progresser en quelques heures en
une maladie foudroyante affectant de multiples organes. C’est pourquoi la me´ningococce´mie est l’une
des causes importantes de la septice´mie. Avant l’arrive´e des traitements antibiotique, la maladie e´tait
associe´e a` un taux de mortalite´ de 70%. En de´pit des progre`s re´alise´s en matie`re de diagnostic et de
traitement, 10 a` 15% des patients affecte´s de´ce`dent de la maladie et 10 a` 20% supple´mentaires souff-
rent de morbidite´s graves (handicap neurologique, perte d’audition, perte d’un membre). La me´ningo-
coccie est toujours une menace sanitaire mondiale importante.
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The ﬁrst cases of meningococcal meningitis were described in
Geneva in 1805 and in New England in 1806, the causative
agent ﬁnally being identiﬁed by Anton Weichselbaum in
1887.1,2 The ﬁrst meningococcal epidemics occurred in
sub-Saharan Africa in the early 1900s and periodic outbreaks
continue to occur worldwide today. Neisseria meningitidis
colonizes the naso-oropharyngeal mucosa in approximately
10–20% of healthy individuals. When it invades the blood-
stream, meningococcus has the potential to cause devastating
disease.3,4 It can affect people of any age, but primarily infects
children and adolescents. Meningococcemia classically follows
an upper respiratory illness consisting of myalgias, fever, head-
ache, and nausea. It can present as an indolent infection with
rapid recovery or progress within a few hours into a fulminant
illness affecting multiple organ systems. As such, meningococ-
cemia is one of the important causes of sepsis.3 Prior to antibi-
otic therapy, the disease carried a 70% mortality rate.5 Despite
advances in early diagnosis and treatment, 10–15% of affected
patients die from the disease and another 10–20% are left with
severe morbidities (neurologic disability, hearing loss, loss of alimb).6,7 Meningococcal disease remains a signiﬁcant global
health threat.
Brief epidemiology, microbiology, and diagnosis
The incidence and timing of meningococcal outbreaks vary
throughout the world. The major inﬂuences on this variability
include the virulence characteristics of different strains, local
vaccination and carriage rates, as well as individual susceptibil-
ity to infection. The incidence of endemic disease is <1–25
cases per 100,000 population per year worldwide. Higher rates
are seen in sub-Saharan Africa from Ethiopia in the east to
Senegal in the west, also known as the ‘‘meningitis belt’’, dur-
ing December–June.8
Neisseria meningitidis is an encapsulated gram-negative
diplococcus that can cause a wide spectrum of disease from
a benign infection to septic shock. It is classiﬁed into sero-
groups based on the immunologic reactivity of its capsular
polysaccharide. The ﬁve most clinically important serogroups
are A, B, C, Y, and W-135.3 Serogroups A, B, and C pre-
dominate worldwide with group A being responsible for
most African outbreaks.9,10 The virulence of meningococcus
176 A. Koyfman, J.K. Takayesuis related to the release of its endotoxin lipopolysaccharide.
This endotoxin is structurally different from that of other
gram-negative bacteria. The level of endotoxin correlates
with disease severity and can be up to 100-fold that of other
gram-negative infections. Humans are the only known
natural reservoir. Transmission is by direct contact with or
inhalation of large droplet nuclei through respiratory
secretions and saliva. Meningitis from hematogenous spread
occurs in about 50% of patients. N. meningitidis can be iso-
lated in up to 75% of patients, but meningococcemia devel-
ops in only 5–20%.3
Several options are available to ascertain the diagnosis
including Gram stain, culture, antigen detection using latex
agglutination, and PCR. Blood, CSF, or skin specimens may
be tested depending on the speciﬁc presentation of the disease.
In the setting of acute infection, the peripheral white blood cell
count is typically elevated, sometimes as high as 65,000/mm3
with a polymorphonuclear predominance and thrombocytope-
nia may be present. White blood cell counts less than 500/mm3
and platelet counts less than 100,000/mm3 are both associated
with poor prognosis. CSF pressure is usually elevated with an
increased protein and decreased glucose level indicative of ac-
tive bacterial replication and metabolism. Gram stain of the
CSF may demonstrate gram-negative diplococci, but can be
free of inﬂammatory cells early in the disease course.11 CSF
can clear within 2 h of antibiotic administration.12 Immunoas-
says may be required cases in which antibiotics have been
administered prior to cultures; PCR testing has demonstrated
sensitivities and speciﬁcities at or above 90% for testing of
CSF, serum, and whole blood.13
Pathophysiology and clinical presentation
Any patient presenting with fever, headache, nausea, vomiting,
myalgias, and a maculopapular or petechial rash should
prompt the consideration of meningococcal infection.14 Pete-
chial rash is the hallmark of invasive meningococcal disease
and may be subtle at ﬁrst, but progress rapidly.15,16 Patients
with invasive meningococcal disease can present in one of four
ways: meningitis only, shock and meningitis, acute mild
meningococcemia (bacteremic with no shock), and fulminant
meningococcemia (bacteremic with shock, no meningitis).
Early on, the patient will present with tachycardia, normal
systolic blood pressure with widened pulse pressure, bounding
peripheral pulses, and warm extremities. As the disease pro-
gresses and hypotension ensues, extremities become cool, and
peripheral pulses are diminished. Death in cases of meningo-
coccemia is secondary to circulatory collapse resulting from
vasodilation, capillary leak, intravascular volume depletion,
and myocardial dysfunction. Tissue hypoxia and acidosis
resulting from an inability to both utilize and receive nutrients
further impairs myocardial function.17 Myocarditis, pericardi-
tis, and/or direct bacterial invasion of the heart further con-
tributes to hemodynamic failure.
Major complications include pulmonary edema, acute
respiratory distress syndrome, disseminated intravascular
coagulation (DIC), adrenal hemorrhage (Waterhouse-Fride-
richsen syndrome), and purpura fulminans. Respiratory com-
plications are secondary to capillary leak. DIC is initiated by
activation of inﬂammatory mediators and can lead to end-or-
gan damage. The progression of skin disease can lead to severe
ecchymoses and limb ischemia as a result of hypoxia, hypoper-fusion, DIC, and direct cutaneous bacterial invasion.17,18
Long-term neurologic sequelae include deafness, mental retar-
dation, seizures, and concentration problems in 10–20% of
survivors.19
Management
Meningococcal disease is a true medical emergency. It re-
quires prompt recognition, early antibiotic therapy, and
intensive patient management. The antibiotic of choice is
high-dose intravenous ceftriaxone because of its good CSF
penetration. Other options include penicillin G, ampicillin,
cefotaxime, and chloramphenicol.3,14,18,20 Ideally, blood cul-
tures should be drawn before antibiotic administration but
antibiotic administration should never be delayed if cultures
are not immediately obtainable. Lumbar puncture should be
performed in hemodynamically stable patients without DIC
not requiring immediate resuscitation. As with blood cul-
tures, antibiotic therapy should not be delayed while waiting
to perform lumbar puncture. Prior to bacterial speciation
and susceptibility results, vancomycin should be added to
cover drug-resistant S. pneumoniae. It is essential to adhere
to local antibiotic resistance patterns to guide treatment as
there will be variability from region to region. There is lim-
ited data to suggest that empiric steroid treatment prior to
the initiation of antibiotic therapy may not be of beneﬁt
in meningitis caused by meningococcus compared to pneu-
moncoccus.21 Meningococcal infection is transmitted by
respiratory droplets, therefore transmission prevention is
achieved with airborne precautions. A surgical mask and
gown should be worn by all persons entering the patient’s
room, especially those within 3 feet (1 m) of the patient or
having contact with patient secretions. These precautions
should remain in place until 24 h after the patient exhibits
no signs of ongoing infection including persistent fever;
new skin lesions; or worsening leukocytosis, headache, con-
fusion or neck stiffness.11
Further management of patients with meningococcal dis-
ease should be directed at restoring adequate oxygen and sub-
strate delivery to the tissues. Intravascular volume should be
repleted with isotonic crystalloid. Vasopressors may be neces-
sary to counteract vasodilatory effects of the lipopolysaccha-
ride endotoxin. Epinephrine and dopamine are good options
because they improve contractility and vasoconstrict dilated
vessels. Intravascular monitoring with central venous catheters
for tracking volume status and intra-arterial blood pressure
monitoring are useful to guide ongoing resuscitation. The role
of steroids for adrenal replacement in septic shock remains un-
clear. If hypotension persists after adequate volume resuscita-
tion and initiation of inotropic support, hydrocortisone should
be considered. Unlike in Haemophilus inﬂuenza type B menin-
gitis, few data exist to support the role of steroids in the pre-
vention of hearing loss in patients with meningococcal
meningitis.18,22 Data is also limited for the use of protein C
concentrate and, to date, this therapy has no proven beneﬁt
on survival.23,24
Airway management may be required for patients with
signiﬁcantly compromised mental status requiring supple-
mental respiratory support or airway protection. Correction
of coagulopathy with FFP is essential to prevent further
complications from DIC such as intracranial hemorrhage,
gastrointestinal bleeding, and hemorrhage into skin lesions.
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based on the presence of multiple features including throm-
bocytopenia, prolongation of PT and aPTT, ﬁbrin degrada-
tion with associated hypoﬁbrinogenemia, and intravascular
thrombosis. The International Society of Thrombosis and
Haemostasis (ISTH) recommends a scoring system based
on these features to diagnose DIC given the variations in
presentation among patients.25 Treatment of DIC is based
on treating the underlying condition rather than the mani-
festations of DIC itself. Due to the ongoing intravascular
destruction of platelets and coagulation factors, platelet
and plasma transfusions are reserved for patients with active
bleeding or undergoing invasive procedures. Prophylactic
transfusion is not recommended.11,25 Patients with thrombo-
sis leading to purpura fulminans or vascular infarction may
require anticoagulation with unfractionated heparin
(10 units/kg/hr); aPTT monitoring is not useful due to the
coincident coagulation disorder.25
Other speciﬁc therapies such renal replacement therapy
(RRT) to correct volume status, electrolyte imbalances, and
acid-base disturbances may be necessary. Some patients may
require amputation of extremities as a result of limb ischemia
resulting from DIC and septic shock.
Antibiotic prophylaxis is recommended for individuals
with close contact to the patient. This is deﬁned as any pro-
longed (>8 h) contact in close proximity (<3 feet) to the
patient and/or direct exposure to oral secretions one week
prior to the onset of the patient’s symptoms until 24 h after
initiation of appropriate antibiotic treatment. Chemoprophy-
laxis is recommended for health care workers whose mouth
or nose is directly exposed to infectious respiratory droplets
or secretions within a distance of 3 feet from an infected per-
son, whether suspected or conﬁrmed. This would include
those providing care to a patient requiring direct contact
(e.g., airway management without wearing a protective
mask).11 Eye exposure alone is not an indication for chemo-
prophylaxis.26 Rifampin is the mainstay prophylactic agent;
although ciproﬂoxacin, azithromycin, and ceftriaxone can
also be used.3,27,28 Chemoprophylaxis is limited by issues
of resistance (e.g., emerging ciproﬂoxacin-resistant strains),
access to drugs, and the large number of people affected
during epidemics, making prevention by vaccination the best
control strategy. Those who most beneﬁt from the vaccine
include college students, military recruits, people with com-
plement or other immune deﬁciencies, post-splenectomy pa-
tients, microbiologists routinely exposed to N. meningitidis
isolates, and people who travel to or reside in countries
where the bacterium is endemic.6,29 Routine immunization
of health care workers is not recommended given the variety
of serotypes possible and the narrow spectra of available
immunizations.
Conﬂict of interest
None.
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Very common disease in Africa
Lots of time dedicated to this topic by WHO
Area ripe for advances since morbidity/mortality still highReferences
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